CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

In 2021, GSK paid Arrowhead Pharmaceuticals $120 million up front for rights to the siRNA drug. Under GSK, GSK4532990 has reached mid-stage clinical development in both MASH and alcohol-related li ...

Biotech company AbbVie (ABBV) said on Wednesday that the U.S. Food and Drug Administration has approved Emrelis medicine for ...

The siRNA technology has has the potential to enable sustained and precise messenger RNA silencing, regulating the expression ...